In vivo drug delivery via contact lenses: The current state of the field from origins to present.

Autor: Wuchte LD; Biomimetic & Biohybrid Materials, Biomedical Devices, & Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, 201 Mullica Hill Road, Glassboro, NJ, 08028, USA., DiPasquale SA; Biomimetic & Biohybrid Materials, Biomedical Devices, & Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, 201 Mullica Hill Road, Glassboro, NJ, 08028, USA.; OcuMedic, Inc, 107 Gilbreth Parkway, Mullica Hill, NJ, 08062, USA., Byrne ME; Biomimetic & Biohybrid Materials, Biomedical Devices, & Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, 201 Mullica Hill Road, Glassboro, NJ, 08028, USA.; OcuMedic, Inc, 107 Gilbreth Parkway, Mullica Hill, NJ, 08062, USA.
Jazyk: angličtina
Zdroj: Journal of drug delivery science and technology [J Drug Deliv Sci Technol] 2021 Jun; Vol. 63. Date of Electronic Publication: 2021 Feb 18.
DOI: 10.1016/j.jddst.2021.102413
Abstrakt: Over the past half century, contact lenses have been investigated for their potential as drug delivery devices for ocular therapeutics. Hundreds of studies have been published in the pursuit of the most effective and efficient release strategies and methods for contact lens drug delivery. This paper provides a thorough overview of the various contact lens drug delivery strategies, with a specific, comprehensive focus on in vivo studies that have been published since the field began in 1965. Significant accomplishments, current trends, as well as future strategies and directions are highlighted. In vivo study analysis provides a straightforward perspective and assessment of method success and commercialization potential in comparison to benchtop, in vitro studies. Analysis of the majority of published work indicates in vitro and in vivo studies do not correlate with a correlation coefficient of 0.25, with many in vitro studies grossly overestimating drug release duration and not showing appreciable drug release control. However, there has been an increase in activity in the last decade, and some methods have generated promising results exhibiting controlled release with commercialization potential. Clinical translation of drug releasing lenses is on the horizon and has high potential to impact a large number of patients providing efficacious treatment compared to current topical treatments.
Competing Interests: Conflict of Interest: Dr. Mark E. Byrne is the Founder and CEO of OcuMedic Inc., and he holds several patents in this research space.
Databáze: MEDLINE
Externí odkaz: